Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

The Development of Medium- and Large-Scale Sustainable Manufacturing Process Platforms for Clinically Compliant Solid Core Nanopharmaceuticals

Objetivo

A number of nanomedicine formulations have enabled, or been shown to hold considerable potential for enabling more effective and less toxic therapeutic interventions. However, progress to date in translating these initiatives to commercial success has been limited. One of the main reasons for this bottleneck is due to the inability of researchers and stakeholders to manufacture batches of the nanomedicine product at the required scale and according to Good Manufacturing Practice (GMP) requirements. The NANOFACTURING project will focus on
- facilitating access to required infrastructures and expertise
- creating GMP pilot lines for up-scaling manufacturing
- addressing the current developmental and production gaps
- taking nanomaterials already successfully produced at proof-of-concept/milligram levels and facilitating their scale-up to sub-kilogram quantities
- providing large-scale and GMP production for clinical trials and nanomedicine translation.
The NANOFACTURING project, through a consortium of 9 partners, will develop the synthetic processes, process control methods, analytical assays for QA/QC, functional specifications, and best practices, interfacing existing R&D centres of excellence, transfer organisations and private GMP manufacturing facilities (including SMEs) to ensure efficient translation from discovery through to first in man, proof-of-concept studies and beyond to Phase III according to industrial and regulatory standards. Specifically, the NANOFACTURING project aims to create a platform process for early, mid- and large-scale manufacturing of glycan-coated gold nanoparticles (GNPs), a widely researched and developed class of self-forming nanoparticles. The ability to engineer new nanopharmaceuticals based on this patent protected platform technology, developed by Midatech Biogune S.L. (Project Coordinator), will have inherent advantages over existing treatments for multiple therapeutic areas.

Convocatoria de propuestas

H2020-NMP-2014-2015

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-NMP-PILOTS-2014

Régimen de financiación

RIA - Research and Innovation action

Coordinador

MIDATECH PHARMA ESPANA SL
Aportación neta de la UEn
€ 2 516 593,75
Dirección
PARQUE TECNOLOGICO DE BIZKAIA EDIFICIO 800 2A PLANTA
48160 Derio
España

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Región
Noreste País Vasco Bizkaia
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 2 516 593,75

Participantes (9)